Enhancer Detail

Comprehensive information about experimentally validated enhancers

About Enhancer
Enhancer ID: E_01107
Species: Homo sapiens
Position : chr20:48900221-48901229
Year: 2019
Title: Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming.
Genome Build: hg19
Enhancer Type: Enhancer
Condition: Disease
Disease Name: hepatocellular carcinoma
PMID:  30659195
MONDO: MONDO:0007256
Tissue: liver
Tissue Ontology ID: UBERON:0002107
Cell Source: Human hepatocellular carcinoma cell
Cell Type: malignant cell
Cell Ontology ID: CL:0001064
Experiment Type: Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation
High Throughput Method: MBDCap-seq, WGBS, ChIP-seq, RNA-seq, Hi-C; whole-genome sequencing
Low Throughput Method: Luciferase Reporter Assay, CRISPR Knockout, ChIP-RT-qPCR, RT-RT-qPCR, Western blot, Bisulfite pyrosequencing; CRISPR-Cas9 endogenous deletion/editing
About Target Gene
Target gene : CEBPB
About TF
TF name : NA
About Regulatory State
Regulatory State : Active
Upstream Pathway Annotation of TF
GeneName Pathway Name Source Gene Number
Enhancer Associated Network
Overlapping Enhancers (hg19) 10 found
Enhancer ID Position Tissue Cell Disease
E_02876 chr20:48400000-49200000 breast malignant cell breast cancer
E_02877 chr20:48400000-49200000 breast malignant cell breast cancer
E_01098 chr20:48900221-48901229 liver hepatoblast hepatocellular carcinoma
E_01105 chr20:48900221-48901229 liver NA hepatocellular carcinoma
E_01106 chr20:48900221-48901229 liver NA hepatocellular carcinoma
E_01108 chr20:48900221-48901229 liver hepatocyte hepatocellular carcinoma
E_01115 chr20:48900221-48901229 liver NA hepatocellular carcinoma
E_01116 chr20:48900221-48901229 liver NA hepatocellular carcinoma
E_01143 chr20:48900221-48901229 uterine cervix NA hepatocellular carcinoma
E_01145 chr20:48900221-48901229 liver NA hepatocellular carcinoma
Expression of Target Genes for the Enhancer